Cargando…

In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis

BACKGROUND & AIMS: A simultaneous decline in pro‐ and anticoagulant drivers in patients with liver diseases results in a “rebalanced” haemostatic system, even in acutely ill patients. Nevertheless, both bleeding and thrombotic events are common. Here, we explored efficacy of pro‐ and antihaemost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisman, Ton, Kleiss, Simone, Patel, Vishal C., Fisher, Caleb, Adelmeijer, Jelle, Bos, Sarah, Singanayagam, Arjuna, Stoy, Sidsel H., Shawcross, Debbie L., Bernal, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cirrhos Is and Liver Failure
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220788/ https://www.ncbi.nlm.nih.gov/pubmed/29768734 http://dx.doi.org/10.1111/liv.13882

Ejemplares similares

Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates
por: Blasi, Annabel, et al.
Publicado: (2021)

Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2023)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF
por: Blasi, Annabel, et al.
Publicado: (2019)

PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis
por: Burza, Maria Antonella, et al.
Publicado: (2014)

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist
por: Shawcross, Debbie L., et al.
Publicado: (2016)

Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin
por: Burlage, Laura C., et al.
Publicado: (2019)

Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis
por: Potze, Wilma, et al.
Publicado: (2014)

Helicobacter pylori infection among patients with liver cirrhosis
por: Pogorzelska, Joanna, et al.
Publicado: (2017)

Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival
por: Blasi, Annabel, et al.
Publicado: (2019)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

High plasma levels of betaine, a trimethylamine N‐Oxide‐related metabolite, are associated with the severity of cirrhosis
por: van den Berg, Eline H., et al.
Publicado: (2022)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)
por: Aspinall, Richard J, et al.
Publicado: (2022)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
por: Jiménez, César, et al.
Publicado: (2022)

Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis
por: Cheng, Xiang-Pu, et al.
Publicado: (2016)

Acute kidney injury is independently associated with death in patients with cirrhosis
por: Scott, Robert A, et al.
Publicado: (2013)

Patient understanding of liver cirrhosis and improvement using multimedia education
por: Goldsworthy, Matthew A, et al.
Publicado: (2017)

Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle
por: Smethurst, Katherine, et al.
Publicado: (2021)

The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
por: Hudson, Mark, et al.
Publicado: (2017)

The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes
por: Schaffner, Carlos A, et al.
Publicado: (2015)

Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients
por: Ohfuji, Satoko, et al.
Publicado: (2014)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

Bacterascites: A study of clinical features, microbiological findings, and clinical significance
por: Oey, Rosalie C., et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis
por: Sanchez, Lukas Otero, et al.
Publicado: (2021)

Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis
por: Arabi, Yaseen M, et al.
Publicado: (2012)

Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020
por: Horhat, Adelina, et al.
Publicado: (2021)

Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors
por: Williams, Sydni, et al.
Publicado: (2021)

Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h
por: McPherson, Stuart, et al.
Publicado: (2016)

Global hemostatic status in patients with acute‐on‐chronic liver failure and septics without underlying liver disease
por: Lisman, Ton, et al.
Publicado: (2020)

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID‐19 patients on anticoagulation
por: Blasi, Annabel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tjq3s2f2ccia8v3kvs4jup8qf0